Par Pharmaceutical Inc, one of the operating companies of Endo International plc (OTC: ENDPQ), announced on Friday that it has started shipping the first generic version of Allergan's Pylera(R) (bismuth subcitrate potassium, metronidazole, tetracycline hydrochloride) 140 mg, 125 mg and 125 mg capsules in the US.
The company has taken this step subsequent to US Food and Drug Administration approval of its Abbreviated New Drug Application.
Bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride capsules, along with omeprazole, are aimed at treating patients with Helicobacter pylori infection and duodenal ulcer disease (active or history of within the past five years) to eradicate H. pylori.
Accord Healthcare introduces Dehydrated Alcohol Injection for cardiovascular indications
CivicaScript introduces low-cost multiple sclerosis treatment
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Glenmark Therapeutics launches Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC)
AB Science secures Canadian patent for AB8939, completing global IP coverage for AML treatment
Avera joins Civica to help maintain drug supplies
Apotex launches generic version of Tasigna in US market
CivicaScript launches droxidopa for symptomatic neurogenic orthostatic hypotension
Padagis' Naloxone HCl Nasal Spray 4 mg obtains extended shelf-life of 36 months
ANI Pharmaceuticals announces US launch of Nitazoxanide Tablets